Given that all the products being developed are based on synthetic cannabidiol, with differences in their formulations, as studies progress their costs gets minimized by leveraging the data from previous studies. This is an important point that was repeated again in the last presentation in reference to the development of BTX1308, BTX 1308 leverages prior data from:
-BTX 1503 acne clinical program
-BTX 1204 AD clinical program
-Permetrex technology clinical studies
Allowing thus for a minimal development pathway and an effective use of funds.
Ann: Investor Presentation, page-40
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.005(1.37%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.0¢ | $391.8K | 1.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 160000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 11013 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
